Oxford BioDynamics Plc (AIM: OBD)

Market Cap	13.86M
Revenue (ttm)	617.00K
Net Income (ttm)	-11.11M
Shares Out	311.86M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,017,606
Open	4.500
Previous Close	4.300
Day's Range	4.100 - 4.950
52-Week Range	4.000 - 52.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2024

About Oxford BioDynamics

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 45
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: OBD

Financial Performance

In 2023, Oxford BioDynamics's revenue was 510,000, an increase of 231.17% compared to the previous year's 154,000. Losses were -10.83 million, 61.3% more than in 2022.